{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:36:04Z","timestamp":1734500164945,"version":"3.30.2"},"reference-count":0,"publisher":"Knowledge E DMCC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJHOSCR"],"abstract":"<jats:p>\r\nBackground: Conditioning regimens are critical for allogeneic hematopoietic cell transplantation (allo-HCT). After unfavorable results using BuCy2 at the beginning of our HCT Program, a restructuring was made with the consequent development of a modified HCT method including a reduced conditioning regimen. The objective of this study was to describe the outcomes using Reduced BuCy2 (rBuCy2) in allo-HCT. \r\nMaterials and Methods: Data from 38 consecutive patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT conditioned with rBuCy2 in a 21-year period were retrospectively analyzed.\r\nResults: Most patients were males (53%) and the median age was 35 years. The most common disease was myelodysplastic syndrome (55%). Toxicity grades III-IV were observed in 44%; and acute and chronic graft-versus-host disease were observed in 26% and 34%, respectively; the median follow-up was 26 months; 30-day non-relapse mortality (NRM) was 3%, and 1 and 2-year NRM were 8%. Ten-year overall survival (OS) was 60%, and 86%, for AML and MDS, respectively.\r\nConclusion: Our rBuCy2 maintains a myeloablative effect, along with immunosuppression for fast engraftment and more importantly, this regimen reduces grades III-IV acute GVHD and NRM in allo-HCT and improves the OS and it appears to be an option for low and middle-income countries.\r\n<\/jats:p>","DOI":"10.18502\/ijhoscr.v16i4.10876","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T09:33:01Z","timestamp":1666085581000},"source":"Crossref","is-referenced-by-count":0,"title":["Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation Do Not Fit All: Adjusting BuCy2 in Mexico to Improve Outcomes in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)"],"prefix":"10.18502","author":[{"given":"Eucario","family":"Le\u00f3n-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica M.","family":"Rivera-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7770","published-online":{"date-parts":[[2022,10,17]]},"container-title":["International Journal of Hematology-Oncology and Stem Cell Research"],"original-title":[],"link":[{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/download\/10876\/10291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/download\/10876\/10291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:14:02Z","timestamp":1734455642000},"score":1,"resource":{"primary":{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/view\/10876"},"secondary":[{"URL":"https:\/\/ijhoscr.tums.ac.ir\/index.php\/ijhoscr\/article\/view\/1423","label":"UNIVERSITY"},{"URL":"https:\/\/publish.kne-publishing.com\/index.php\/IJHOSCR\/article\/view\/10876","label":"PUBLISHER"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":0,"URL":"https:\/\/doi.org\/10.18502\/ijhoscr.v16i4.10876","relation":{},"ISSN":["2008-2207"],"issn-type":[{"type":"electronic","value":"2008-2207"}],"subject":[],"published":{"date-parts":[[2022,10,17]]}}}